MYMX - Mymetics secures Swiss grant to advance virosome-based COVID-19 vaccine

Mymetics (MYMX) subsidiary and Insel Gruppe AG have been awarded a grant from the Swiss Innovation Agency, which will allow Mymetics in collaboration with Bern University to start a preclinical study investigating MYMX's virosome-based COVID-19 nasal vaccine candidate to block nasal infection and virus spreading to the lungs and brain. With the nasal vaccine, Mymetics aims to elicit not only a systemic, but also a protective respiratory immunity with a local memory mucosal immunity, which is often poorly induced by standard intramuscular vaccination.This new study will complement Mymetics' other ongoing preclinical COVID-19 studies in U.S. and Germany.

For further details see:

Mymetics secures Swiss grant to advance virosome-based COVID-19 vaccine